DATA GRAPHICS | Market Access
Financial impact of Part B rebates may be minimal
BioCentury estimates manufacturers could have to pay roughly $29M in rebates for drugs with price increases CMS says exceeded inflation
March 18, 2023 12:53 AM UTC
Manufacturers will owe Medicare about $29 million under the Inflation Reduction Act’s Part B Medicare Prescription Drug Inflation Rebate Program, according to an analysis by BioCentury. The relatively small amount indicates that few manufacturers increased prices substantially more than inflation heading into this year.
Under the Inflation Reduction Act, if the reference price of a drug covered by Part B exceeds its inflation-adjusted benchmark in any given year, manufacturers must pay an inflation rebate. ...